logo

For the Inventor, By the Inventor

Sandwich, United Kingdom

John Steele

USPTO Granted Patents = 15

Average Co-Inventor Count = 3.6

ph-index = 4

Forward Citations = 49(Granted Patents)


Location History:

  • Deal, GB (1990)
  • Sandwich, GB (1989 - 2005)
  • Kent, GB (2005)

Company Filing History:

goldMedal15 out of 4,455 
 
Pfizer Corporation
 patents

Years Active: 1989-2005

Loading Chart...
15 patents (USPTO):Explore Patents
1. 6958402 - 3-(imidazolyl)-2-alkoxypropanoic acids (2005-10-25),
2. 6949577 - Pharmaceuticals (2005-09-27),
3. 6919457 - 3-(imidazolyl)-2-aminopropanoic acids (2005-07-19),
4. 6759426 - 3-(Imidazolyl)-2-aminopropanoic acids (2004-07-06),
5. 6713496 - 3-(imidazolyl)-2-alkoxypropanoic acids (2004-03-30),
6. 5744488 - Indole derivatives thromboxane A2 antagonists (1998-04-28),
7. 5705523 - Pyridine- and imidazole-derived agents for cardiovascular diseases (1998-01-06),
8. 5618941 - Benzenealkanoic acids for cardiovascular diseases (1997-04-08),
9. 5457118 - Pyridine derived agents for cardiovascular diseases (1995-10-10),
10. 5149814 - Alkyl 2-benzylidene-4-(2-alkylimidazopyrid-1-yl) benzoylacetate esters (1992-09-22),
11. 5120747 - Platelet activating factor antagonists (1992-06-09),
12. 5070205 - Alkyl 2-benzylidene-4-(benzimidazol-1-yl) benzoylacetate esters as (1991-12-03),
13. 4963560 - 1,4-dihydropyridine derivatives (1990-10-16),
14. 4935430 - Platelet activating factor antagonists (1990-06-19),
15. 4859686 - Dihydropyridine anti-allergic and anti-inflammatory agents (1989-08-22),

Title: John Steele: Innovator in Pharmaceutical Compounds

Introduction

John Steele is a prominent inventor based in Sandwich, GB. He has made significant contributions to the field of pharmaceuticals, holding a total of 15 patents. His work focuses on developing innovative compounds that address various medical conditions.

Latest Patents

One of John Steele's latest patents involves the creation of 3-(imidazolyl)-2-alkoxypropanoic acids. These compounds, represented by a specific formula, are designed to be useful in treating thrombotic conditions and other pathologies associated with fibrin deposition. The invention provides a class of TAFIa inhibitors that can be utilized in treating conditions such as thrombosis, atherosclerosis, adhesions, dermal scarring, cancer, fibrotic conditions, and inflammatory diseases. The compounds also aim to maintain or enhance bradykinin levels in the body, showcasing their potential therapeutic benefits.

Career Highlights

John Steele is currently associated with Pfizer Corporation, a leading global pharmaceutical company. His work at Pfizer has allowed him to focus on innovative research and development in the pharmaceutical sector. His contributions have been instrumental in advancing the understanding and treatment of various medical conditions.

Collaborations

Throughout his career, John has collaborated with notable colleagues, including Kenneth Richardson and Charlotte Moira Norfor Allerton. These collaborations have fostered a productive environment for innovation and have led to the development of groundbreaking pharmaceutical solutions.

Conclusion

John Steele's work exemplifies the impact of innovation in the pharmaceutical industry. His patents and collaborations continue to contribute to advancements in medical treatments, highlighting the importance of research and development in improving health outcomes.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…